Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEARTOX haemodialysis lipid infusion study for protein-bound uremic toxin clearance
2023-510406-41-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of soybean oil + medium-chain triglycerides in chronic kidney disease (CKD) and kidney failure (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Clearance of p-cresyl sulfate during hemodialysis. Planned start Nov 2024; status: authorised.
02
Drugs
soybean oil + medium-chain triglycerides
03
Conditions
chronic kidney disease (CKD)kidney failure
Beyond the preview
Go deeper on 2023-510406-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510406-41-00.